nach oben

Journal of Neurology

Erschienen in:

24.04.2020 | Review

Levodopa challenge test: indications, protocol, and guide

verfasst von: Gerard Saranza, Anthony E. Lang

Erschienen in: Journal of Neurology | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

A drug challenge test in Parkinson’s disease, such as the levodopa challenge test (LCT), is an easy and generally safe procedure, which has been used by clinicians for various indications. The results of the test have significant implications in the management of patients, from preoperative evaluation for deep brain stimulation to providing the basis for medication adjustments to address motor or non-motor fluctuations and dyskinesias. This paper reviews the different indications and protocols commonly used in an acute LCT. Potential complications of the procedure and an overview of levodopa responsiveness and unresponsiveness are also discussed.

Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386:896–912. https://doi.org/10.1016/S0140-6736(14)61393-3CrossRefPubMed

Anderson E, Nutt J (2011) The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications. Parkinsonism Relat Disord 17:587–592. https://doi.org/10.1016/j.parkreldis.2011.03.014CrossRefPubMed

Nutt J, Carter J, Woodward W (1995) Long-duration response to levodopa. Neurology 45:1613–1616CrossRef

Albanese A, Bonuccelli U, Brefel C et al (2001) Consensus statement on the role of acute dopaminergic challenge in Parkinson’s disease. Mov Disord 16:197–201CrossRef

Merello M, Nouzeilles MI, Arce GP, Leiguarda R (2002) Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson’s disease diagnosis. Mov Disord 17:795–798. https://doi.org/10.1002/mds.10123CrossRefPubMed

Defer GL, Widner H, Marié RM et al (1999) Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD). Mov Disord 14:572–584. https://doi.org/10.1002/1531-8257(199907)14:4%3c572:AID-MDS1005%3e3.0.CO;2-CCrossRefPubMed

Langston JW, Widner H, Goetz CG et al (1992) Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 7:2–13. https://doi.org/10.1002/mds.870070103CrossRefPubMed

Lindvall O, Rehncrona S, Brundin P et al (1989) Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson’s disease: a detailed account of methodology and a 6-month follow-up. JAMA Neurol 46:615–631. https://doi.org/10.1001/archneur.1989.00520420033021CrossRef

Lang AE, Widner H (2002) Deep brain stimulation for Parkinson’s disease: patient selection and evaluation. Mov Disord 17:S94–S101. https://doi.org/10.1002/mds.10149CrossRefPubMed

10.

Machado A, Fernandez HH, Deogaonkar M (2012) Deep brain stimulation: what can patients expect from it? Cleve Clin J Med 79:113–120. https://doi.org/10.3949/ccjm.78gr.11006CrossRefPubMed

11.

Abbruzzese G, Barone P, Bonuccelli U et al (2012) Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson’s disease: efficacy, safety and patient selection. Funct Neurol 27:147–154PubMed

12.

Fernandez HH, Standaert DG, Hauser RA et al (2015) Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord 30:500–509. https://doi.org/10.1002/mds.26123CrossRefPubMed

13.

Rabel C, Le Goff F, Lefaucheur R et al (2016) Subjective perceived motor improvement after acute levodopa challenge in Parkinson’s disease. J Parkinsons Dis 6:779–785. https://doi.org/10.3233/JPD-160906CrossRefPubMed

14.

Schade S, Sixel-Döring F, Ebentheuer J et al (2017) Acute levodopa challenge test in patients with de novo Parkinson’s disease: data from the DeNoPa cohort. Mov Disord Clin Pract 4:755–762. https://doi.org/10.1002/mdc3.12511CrossRefPubMedPubMedCentral

15.

Ko P-W, Kang K, Lee H-W (2018) Levodopa-induced respiratory dysfunction confirmed by levodopa challenge test: a case report. Medicine (Baltimore) 97:e12488–e12488. https://doi.org/10.1097/MD.0000000000012488CrossRef

16.

Fabbri M, Coelho M, Guedes LC et al (2017) Response of non-motor symptoms to levodopa in late-stage Parkinson’s disease: results of a levodopa challenge test. Parkinsonism Relat Disord 39:37–43. https://doi.org/10.1016/j.parkreldis.2017.02.007CrossRefPubMed

17.

Rosqvist K, Odin P, Hagell P et al (2018) Dopaminergic effect on non-motor symptoms in late stage Parkinson’s disease. J Parkinsons Dis 8:409–420. https://doi.org/10.3233/JPD-181380CrossRefPubMed

18.

Berardelli A, Wenning GK, Antonini A et al (2013) EFNS/MDS-ES recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol 20:16–34. https://doi.org/10.1111/ene.12022CrossRefPubMed

19.

Zappia M, Colao R, Montesanti R et al (1997) Long duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson’s disease. Ann Neurol 42:245–248. https://doi.org/10.1002/ana.410420217CrossRefPubMed

20.

Terroba Chambi C, Rossi M, Bril A et al (2017) Diagnostic value of combined acute levodopa challenge and olfactory testing to predict Parkinson’s disease. Mov Disord Clin Pract 4:824–828. https://doi.org/10.1002/mdc3.12517CrossRefPubMedPubMedCentral

21.

Asayama S, Wate R, Kaneko S et al (2013) Levodopa challenge test and 123I-metaiodobenzylguanidine scintigraphy for diagnosing Parkinson’s disease. Acta Neurol Scand 128:160–165. https://doi.org/10.1111/ane.12104CrossRefPubMed

22.

Okun MS, Tagliati M, Pourfar M et al (2005) Management of referred deep brain stimulation failures. Arch Neurol 62:1250. https://doi.org/10.1001/archneur.62.8.noc40425CrossRefPubMed

23.

Suchowersky O, Reich S, Perlmutter J et al (2006) Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review). Neurology 66:968–975. https://doi.org/10.1212/01.wnl.0000215437.80053.d0CrossRefPubMed

24.

National Collaborating Centre for Chronic Conditions (Great Britain) (2017) Parkinson’s disease: national clinical guideline for diagnosis and management in primary and secondary care. Royal College of Physicians, London

25.

Clarke CE (2002) Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 69:590–594. https://doi.org/10.1136/jnnp.69.5.590CrossRef

26.

Levin J, Kurz A, Arzberger T et al (2016) ÜBERSICHTSARBEIT: Differenzialdiagnose und Therapie der atypischen Parkinson-syndrome. Dtsch Arztebl Int 113:61–69. https://doi.org/10.3238/arztebl.2016.0061CrossRefPubMedPubMedCentral

27.

Vasta R, Nicoletti A, Mostile G et al (2017) Side effects induced by the acute levodopa challenge in Parkinson’s disease and atypical parkinsonisms. PLoS ONE 12:1–6. https://doi.org/10.1371/journal.pone.0172145CrossRef

28.

Estévez S, Perez-Lloret S, Merello M (2009) Does clinical intolerance to a diagnostic acute levodopa challenge differentiate multiple system atrophy from pd? Int J Neurosci 119:2257–2261. https://doi.org/10.3109/00207450903139721CrossRefPubMed

29.

Müller T, Benz S, Przuntek H (2000) Choice reaction time after levodopa challenge in parkinsonian patients. J Neurol Sci 181:98–103. https://doi.org/10.1016/S0022-510X(00)00436-6CrossRefPubMed

30.

Müller T, Benz S (2002) Quantification of the dopaminergic response in Parkinson’s disease. Parkinsonism Relat Disord 8:181–186. https://doi.org/10.1016/S1353-8020(01)00010-4CrossRefPubMed

31.

Rhew K, Han N, Oh JM (2019) Impact of safety warning on domperidone prescribing for geriatric patients in South Korea: analysis of national insurance claim data. Int J Environ Res Public Health. https://doi.org/10.3390/ijerph16162985CrossRefPubMedPubMedCentral

32.

Sethi K (2008) Levodopa unresponsive symptoms in Parkinson disease. Mov Disord 23:S521–S533. https://doi.org/10.1002/mds.22049CrossRefPubMed

33.

Feng T, Li W, Lu L et al (2009) Acute stepwise challenge test with levodopa in treated patients with parkinsonism. Parkinsonism Relat Disord 15:354–358. https://doi.org/10.1016/j.parkreldis.2008.08.010CrossRefPubMed

34.

Castrioto A, Kistner A, Klinger H et al (2013) Psychostimulant effect of levodopa: reversing sensitisation is possible. J Neurol Neurosurg Psychiatry 84:18–22. https://doi.org/10.1136/jnnp-2012-302444CrossRefPubMed

35.

Fabbri M, Coelho M, Abreu D et al (2016) Do patients with late-stage Parkinson’s disease still respond to levodopa? Parkinsonism Relat Disord 26:10–16. https://doi.org/10.1016/j.parkreldis.2016.02.021CrossRefPubMed

36.

Ruonala V, Tarvainen MP, Karjalainen PA et al (2015) Autonomic nervous system response to L-dopa in patients with advanced Parkinson’s disease. Proc Annu Int Conf IEEE Eng Med Biol Soc EMBS 2015:6162–6165. https://doi.org/10.1109/EMBC.2015.7319799CrossRef

37.

Lucetti C, Logi C, Del Dotto P et al (2010) Levodopa response in dementia with Lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord 16:522–526. https://doi.org/10.1016/j.parkreldis.2010.06.004CrossRefPubMed

38.

Khor S-P, Hsu A (2007) The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson’s disease. Curr Clin Pharmacol 2:234–243. https://doi.org/10.2174/157488407781668802CrossRefPubMed

39.

Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement disorder society-sponsored revision of the unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129–2170. https://doi.org/10.1002/mds.22340CrossRefPubMed

40.

Goetz CG, Nutt JG, Stebbins GT (2008) The unified dyskinesia rating scale: presentation and clinimetric profile. Mov Disord 23:2398–2403. https://doi.org/10.1002/mds.22341CrossRefPubMed

41.

Morishita T, Rahman M, Foote KD et al (2011) DBS candidates that fall short on a levodopa challenge test: alternative and important indications. Neurologist 17:263–268. https://doi.org/10.1097/NRL.0b013e31822d1069CrossRefPubMedPubMedCentral

42.

Merello M, Gerschcovich ER, Ballesteros D, Cerquetti D (2011) Correlation between the movement disorders society unified Parkinson’s Disease rating scale (MDS-UPDRS) and the Unified Parkinson’s Disease rating scale (UPDRS) during l-dopa acute challenge. Parkinsonism Relat Disord 17:705–707. https://doi.org/10.1016/j.parkreldis.2011.07.002CrossRefPubMed

43.

Warnecke T, Suttrup I, Schröder JB et al (2016) Levodopa responsiveness of dysphagia in advanced Parkinson’s disease and reliability testing of the FEES-Levodopa-test. Parkinsonism Relat Disord 28:100–106. https://doi.org/10.1016/j.parkreldis.2016.04.034CrossRefPubMed

44.

Fabbri M, Marini C, Bisulli F et al (2013) Clinical and polygraphic study of familial paroxysmal kinesigenic dyskinesia with PRRT2 mutation. Epileptic Disord 15:123–127. https://doi.org/10.1684/epd.2013.0569CrossRefPubMed

45.

Lechien JR, Blecic S, Ghosez Y et al (2018) Voice quality and orofacial strength as outcome of levodopa effectiveness in patients with early idiopathic parkinson disease: a preliminary report. J Voice. https://doi.org/10.1016/j.jvoice.2018.04.002CrossRefPubMed

46.

Seiffert P, Derejczyk J, Kawa J et al (2017) Frailty phenotype and the role of levodopa challenge test in geriatric inpatients with mild parkinsonian signs. Biogerontology 18:641–650. https://doi.org/10.1007/s10522-017-9716-6CrossRefPubMed

47.

Gao J, Du LJ, He W et al (2016) Ultrasound strain elastography in assessment of muscle stiffness in acute levodopa challenge test: a feasibility study. Ultrasound Med Biol 42:1084–1089. https://doi.org/10.1016/j.ultrasmedbio.2015.12.014CrossRefPubMed

48.

Chaudhuri KR, Schrag A, Weintraub D et al (2019) The movement disorder society nonmotor rating scale: initial validation study. Mov Disord. https://doi.org/10.1002/mds.27862CrossRefPubMedPubMedCentral

49.

Wider C, Russmann H, Villemure J-G et al (2006) Long-duration response to levodopa in patients with advanced parkinson disease treated with subthalamic deep brain stimulation. JAMA Neurol 63:951–955. https://doi.org/10.1001/archneur.63.7.951CrossRef

50.

Ogawa N (2000) Factors affecting levodopa effects in Parkinson’s disease. Acta Med Okayama 54:95–101PubMed

51.

Quattrone A, Zappia M, Aguglia U et al (1995) The subacute levodopa test for evaluating long-duration response in Parkinson’s disease. Ann Neurol 38:389–395. https://doi.org/10.1002/ana.410380308CrossRefPubMed

52.

Parkinson Study Group (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498–2508. https://doi.org/10.1056/NEJMoa033447CrossRef

53.

Ikebe SI, Harada T, Hashimoto T et al (2003) Prevention and treatment of malignant syndrome in Parkinson’s disease: a consensus statement of the malignant syndrome research group. Parkinsonism Relat Disord 9:47–49. https://doi.org/10.1016/S1353-8020(02)00123-2CrossRef

54.

Rossi P, Colosimo C, Moro E, Tonali PAA (2001) Acute challenge with apomorphine and levodopa in parkinsonism. Focus Parkinson's Dis 13:60–63. https://doi.org/10.1159/000008142CrossRef

Titel: Levodopa challenge test: indications, protocol, and guide
verfasst von: Gerard Saranza
Anthony E. Lang
Publikationsdatum: 24.04.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 9/2021
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-09810-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2021

When does postural instability appear in monogenic parkinsonisms? An individual-patient meta-analysis

Neurofilaments in progressive multiple sclerosis: a systematic review

Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone

A solution to PET brain motion artefact

Serum and CSF alpha-synuclein levels do not change in COVID-19 patients with neurological symptoms